When
Where
Runde auditorium, Domus Medica, University of Oslo
Organizer
Advancing radiopharmaceuticals from bench to bedside requires integrated preclinical infrastructure, reliable access to radionuclides, and cross-sector collaboration. This symposium will highlight how strengthened preclinical capabilities can fast-track clinical translation, mapping Norway’s existing strengths, identifying gaps, and defining opportunities to position the Oslo region as a leading radiopharmaceutical research hub.
This meeting convenes hospitals, preclinical and clinical researchers, emerging radiopharma companies, global pharma, and ecosystem partners to exchange international best practices, share national initiatives, and discuss strategic priorities for establishing Norway as a preferred destination for radiopharmaceutical preclinical and clinical research.
An in-depth overview of the Oslo radiopharmaceutical ecosystem, showcasing contributions from leading industry players, CDMOs, and global pharma. Sessions highlight current R&D capabilities, GMP manufacturing advancements, and the region’s growing role as a competitive hub for radiopharmaceutical innovation and collaboration.
Dedicated sessions explore Oslo’s preclinical ecosystem, including comparative medicine infrastructure, imaging platforms, and translational capabilities. Emphasis is placed on bridging discovery to clinical application through integrated facilities and coordinated efforts across academia, hospitals, and industry.
A forward-looking panel discussion addressing industry needs and ambitions in preclinical dosimetry. Focus on standardization, scalability, and regulatory alignment to enable efficient clinical translation of radiopharmaceuticals, positioning Oslo as a leader in next-generation therapeutic development.
Bent Wilhelm Schoultz: bent.wilhelm.schoultz@syklotronsenteret.no
Syed Nuruddin: syed.nuruddin@syklotronsenteret.no
Ingrid Norberg-Schulz Hagen: ingrid.hagen@syklotronsenteret.no